Assessing human health risks of chemicals and drugs: An overview

Human and Ecological Risk Assessment (HERA)

Volumn 3, Issue 4, 1997, Pages 599-615

  Suh, Duck H ^a   Abdel Rahman, Mohamed S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Risk assessment; Uncertainty factor

Indexed keywords

EID: 21944434223     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/10807039709383715     Document Type: Article

References (7)

1. Abdel-Rahman, M.S. and Kadry, A.M. 1995. Studies on the use of uncertainty factors in deriving RfDs. Human and Ecol. Risk Assess. 1(5), 614-624.
2. Armayar, G.M. and Lopez, L.M. 1988. Lisinopril: A new angiotensin-converting enzyme inhibitor. Drug Intelleg. Clin. Pharm. 22, 365-372.
3. Baba, T., Tomijama, T., Murabayashi, S., Tomijama, M., and Takebe, K. 1989. Enalapril pharmacokinetics in diabetic patients. The Lancet. 1, 226-227.
4. Barnes, D.G. and Dourson, M.L. 1988. Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486.
5. 2-receptor antagonist. Dr. J. Pharmacol. 66, 464p.
6. Calabrese, E.J. 1985. Uncertainty factors and interindividual variation. Regul. Toxicol. Pharmacol. 5, 190-196.
7. Calabrese, E.J., Callahan, B.G., Hinman, M.L., and Chapman, P.M. 1995. Human and Ecol. Risk Assess. 1, 5.